GENE ONLINE|News &
Opinion
Blog

2025-11-28|

Study Finds Nigrosome Integrity Has Limited Predictive Value for Motor Outcomes in Parkinson’s DBS Patients

by GOAI
Share To

A recent study published in *npj Parkinson’s Disease* examined the relationship between preoperative nigrosome integrity and motor outcomes in Parkinson’s disease patients undergoing deep brain stimulation (DBS). Researchers found that the structural preservation of nigrosomes, a subset of dopamine-producing neurons, has limited predictive value for determining the effectiveness of DBS in improving motor function. This challenges previous assumptions about the role of nigrosome integrity as a reliable indicator for DBS success.

The study analyzed data from Parkinson’s disease patients who underwent DBS treatment, focusing on whether preoperative imaging of nigrosomes could forecast improvements in motor symptoms. Nigrosomes are located within the substantia nigra region of the brain and are known to be affected by neurodegeneration in Parkinson’s disease. Despite their involvement in dopamine production, researchers observed no significant correlation between their structural condition prior to surgery and post-DBS motor outcomes. These findings suggest that other factors may play a more critical role in predicting patient response to DBS therapy.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top